Bayer Sinks 3.9% — Litigation Discount Deepens
BAYRY closed at $13.89, off $0.57, hitting what is now a multi-year ADR low as the Roundup liability overhang continues to erode the equity story. With the balance sheet already stretched and no clear litigation settlement timeline, the market is pricing this as a restructuring candidate, not a recovery play. Watch for any Q3 earnings pre-announcement next week — a guidance cut here reopens the $12 handle.